Therefore, it is necessary to develop anti‐cancer drugs that inhibit both ZEB1 and ZEB2 simultaneously, because ZEB1/2 are both deeply involved in the malignant differentiation of cancer cells. This evidence concerns the gene ZEB1 and cancer.